RxDoctor Payments Data

Elizabeth Sharp-Marsden, APRN

Family · Idaho Falls, IDNPI 1740771898

Payments from drug & device makers

$980in general payments, 2019–2025

Across 36 payments — averaging $27.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$481
  • Vanda Pharmaceuticals Inc.$164
  • Astellas Pharma US Inc$139
  • Lilly USA, LLC$33
  • Bristol Myers Squibb$33
  • Shield Therapeutics Inc$26
  • plus $104 from 7 others

What the payments were for

  • Food & beverage$980100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$980 in reported general payments places this provider in the 70th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$13,249
Medicare patients
44
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl13$21,800
MounjaroTirzepatide12$12,902
Levothyroxine Sodium115$1,148
Amitriptyline Hcl21$418
Estradiol20$410
Bupropion XlBupropion Hcl24$311
Hydroxyzine Hcl13$307
Sumatriptan Succinate16$302
Famotidine22$280
Gabapentin15$230
Omeprazole23$217
Atorvastatin Calcium27$169
Losartan Potassium49$158
Sertraline Hcl25$147
Nifedipine ErNifedipine12$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$481$21,80013 claims
Lilly USA, LLCMounjaro$33$12,90212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 809 family providers in Idaho.

Other family in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →